mRx-7: A new weapon for cancer
LEARN MORE
miReven is commercialising the pioneering work of Prof Peter Leedman and Dr Keith Giles at the Harry Perkins Institute of Medical Research on the anti-cancer potential of
miR-7
LEARN MORE

miReven

miReven is a biopharmaceutical company focused on developing mRx-7 as a new cancer therapy. The world of RNA-based therapeutics is an entirely new clinical treatment

Our Science

mRx-7 is a synthetic small double stranded RNA (dsRNA) chemically modified mimic of microRNA-7 (miR-7) that we have designed, which is a potent inhibitor of…

Investors

miReven welcomes new partnerships Please contact us for information about investing in our company

microRNA replacement therapy

microRNA replacement therapy

microRNAs are tiny molecules that are encoded in the DNA within our cells. They are responsible for controlling expression of genes that dictate how the cell behaves, including deciding when to divide or move. In some cancers the amount of

A novel approach for treating cancers

Recent News

News

miReven scientists publish in Hepatology

miReven scientists publish paper in prestigious journal Hepatology identifying new pathways that mediate resistance to sorafenib and showing that microRNA-7 can overcome therapeutic resistance in

Learn More

Contact Us

Name*
This field is for validation purposes and should be left unchanged.